Effectiveness of tranexamic acid in orthognathic surgery: A systematic review of systematic reviews.


Journal

Journal of stomatology, oral and maxillofacial surgery
ISSN: 2468-7855
Titre abrégé: J Stomatol Oral Maxillofac Surg
Pays: France
ID NLM: 101701089

Informations de publication

Date de publication:
Dec 2023
Historique:
received: 11 07 2023
revised: 05 08 2023
accepted: 06 08 2023
medline: 11 12 2023
pubmed: 10 8 2023
entrez: 9 8 2023
Statut: ppublish

Résumé

This study aimed to review the currently available evidence on the effectiveness of administering tranexamic acid (TXA) to patients undergoing orthognathic surgery. A study protocol was developed in accordance with the Preferred Reporting Guideline for Overviews of Reviews (PRIOR) and registered on the International Prospective Register of Systematic Reviews (PROSPERO) under Registration No. CRD42021232931. Furthermore, the reporting of the present systematic review was performed based on the PRISMA checklist. The search strategy yielded a total of 50 articles. After reading the abstracts, 28 articles were excluded, and the English full texts of the remaining 22 studies were separately examined for eligibility by two authors; 15 articles were excluded because they did not meet the inclusion criteria. Finally, seven systematic reviews and meta-analysis satisfied the criteria for inclusion and were processed for critical review evaluation. Within the limits of the present study and the reviews of the 7 articles included, it is observed that TXA is able to reduce the amount of intraoperative blood loss and the amount of irrigation fluids required. However, it does not influence postoperative levels of hemoglobin or hematocrit, nor does it affect the requirement for blood transfusions. It was interestingly discovered that TXA could increase the quality of the surgical site. These data imply that TXA may be an effective adjuvant in lowering bleeding during orthognathic surgery. As a result, the potential risk of problems related with considerable blood loss may be minimized.

Identifiants

pubmed: 37558181
pii: S2468-7855(23)00213-6
doi: 10.1016/j.jormas.2023.101592
pii:
doi:

Substances chimiques

Tranexamic Acid 6T84R30KC1
Antifibrinolytic Agents 0

Types de publication

Systematic Review Meta-Analysis Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

101592

Informations de copyright

Copyright © 2023 Elsevier Masson SAS. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interests The authors have no relevant financial or non-financial interests to disclose.

Auteurs

Feras AlMofreh AlQahtani (FA)

Oral and Maxillofacial Surgery Senior House Officer, AlKhobar, Saudi Arabia. Electronic address: Ferasalqahtani11@gmail.com.

Sam Thomas Kuriadom (ST)

Associate Professor, College of Dentistry, Center of Medical and Bio-allied Health Sciences Research, Ajman University, Ajman, United Arab Emirates.

Sudhir Varma (S)

Assistant Professor, College of Dentistry, Center of Medical and Bio-allied Health Sciences Research, Ajman University, Ajman, United Arab Emirates.

Hamedy AlAnzy (H)

General Dentist. University of Sharjah. United Arab Emirates.

Sami AlOtaibi (S)

Associate Professor, Department of Oral and Maxillofacial Surgery, King Saud University, Saudi Arabia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH